Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Clinical Management of Bullous Pemphigoid: Key Questions and Considerations
Description
The presentation discusses the clinical management of bullous pemphigoid (BP), focusing on key questions related to treatment. Initial patient assessment includes evaluating prognostic factors like age, general health, and comorbidities, which can influence treatment decisions. Screening for skin lesion extent is crucial for appropriate therapy, as extensive lesions necessitate more aggressive treatments. The use of global scoring systems, such as the IGA score and BPDAI score, helps in assessing the severity of BP. The talk also highlights the importance of understanding the patient’s educational needs regarding treatments, vaccination risks, particularly about COVID-19, and the implications of drug interactions that might trigger BP flares. The choice between topical and oral corticosteroids is debated, with evidence supporting the superiority of topical treatments in terms of efficacy and reduced mortality. While immunosuppressive therapies like azathioprine and methotrexate are discussed, their benefits appear limited due to high adverse event rates. The role of biologics like rituximab and omalizumab is examined, acknowledging their potential but emphasizing the need for caution due to associated risks in elderly patients. Overall, the management of BP should be individualized, consider patient conditions comprehensively, and adapt to emerging evidence from ongoing trials.
View moreConclusions
- Pretherapeutic screening should include evaluating patient age, general condition, and comorbidities to assess treatment risks.
- Both patient's Karnofsky score and age significantly predict prognosis in bullous pemphigoid (BP).
- Comorbidities such as neurological disorders, diabetes, and cardiovascular issues are major prognostic factors for BP patients.
- The extent of skin lesions must influence treatment choices, as extensive lesions should not be treated with dapsone or tetracyclines.
- Oral corticosteroids are generally less preferred compared to topical corticosteroids due to higher associated mortality risks.
- Topical corticosteroids have been shown to significantly decrease mortality in BP patients compared to oral corticosteroids.
- High doses of prednisone are associated with poor tolerance and higher risk of mortality.
- Conventional immunosuppressants like azathioprine and methotrexate do not show significant corticosteroid-sparing effects in BP treatment.
- Tetracyclines may be used in patients with mild to moderate BP but often need to be combined with corticosteroids for effective results.
- Biologic treatments like rituximab and omalizumab may provide options for treatment-resistant BP, although evidence is limited and off-label use is a concern.
- Joly P et al. J Am Acad Dermatol. 2022
- Ou S et al. J Am Acad Dermatol. 2024
- Kasperkiewicz M et al. Br J Dermatol. 2022
- Liu SD, Chen WT, Chi CC. JAMA Dermatol. 2020
- Montagnon C et al. J Am Acad Dermatol 2021
- Borradori L et al. JEADV 2022
- Kridin K et al. J Am Acad Dermatol 2024
- Beissert S et al. Arch Dermatol. 2007 Dec;143(12):1536-42
- Sticherling M et al. Br J Dermatol. 2017
- Williams HC et al. Lancet 2017
- Micallef D, Harman KE. Br J Dermatol. 2021; 185 (Suppl. 1): 8-9
- Berkani N et al. Sci Rep. 2019
- Chenabni R et al. Br J Dermatol 2024
- Moghadam P et al Br J Dermatol 2023
- Zhao L et al JAMA 2023